A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 10, 2005, Pages 1366-1372

  Emsley, H C A ^b   Smith, C J ^a   Georgiou, R F ^a   Vail, A ^a   Hopkins, S J ^c   Rothwell, N J ^a   Tyrrell, P J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN INFARCTION SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; NEUTROPHIL; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; AGED; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 25444517949     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.054882     Document Type: Article

References (34)

1. Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 2003;17:152-7.
2. Arena WP. The balance between IL-1 and IL-1ra in disease. Cytokine Growth Factor Rev 2002;13:323-40.
3. Mulcahy NJ, Ross J, Rothwell NJ, et al. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 2003;140:471-46.
4. Touzani O, Boutin H, Chuquet J, et al. Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J Neuroimmunol 1999;100:203-15.
5. Gutierrez EG, Banks WA, Kastin AJ. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol 1994;55:153-60.
6. Cohen SB, Rubbert A. Bringing the clinical experience with anakinra to the patient. Rheumatology 2003;42(suppl 2):36-40.
7. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase three, randomised, double-blind, placebo-controlled, multicentre trial. Crit Care Med 1997;25:1115-21.
8. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH stroke scale using video training. Stroke 1994;25:2220-6.
9. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1998;19:604-7.
10. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md Med J 1965;14:61-5.
11. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-6.
12. Gavin CM, Smith CJ, Emsley HCA, et al. Reliability of a semi-automated technique of cerebral infarct volume measurement with computed tomography. Cerebrovasc Dis 2004;18:220-6.
13. Emsley HCA, Smith O, Gavin CM, et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003;139:93-101.
14. CPMP Working Party on Efficacy of Medicinal Products. EEC Note For guidance: good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990;67:361-72.
15. Medical Research Council. Guidelines for good clinical practice in clinical trials, Medical Research Council, London, 1998.
16. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:109-17.
17. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
18. Heiss WD. Ischemic penumbra: evidence from functional imaging in man. J Cereb Blood Flow Metab 2000;20:1276-93.
19. Kim DC, Reitz B, Carmichael DF, et al. Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist. J Pharm Sci 1995;84:575-80.
20. Fisher CJ Jr, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomised, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.
21. Martin D, Chinookoswong N, Miller G. The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp Neurol 1994;130:362-7.
22. Beamer NB, Coull BM, Clark WM, et al. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol 1995;37:800-4.
23. Muir KW. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke 2002;33:1545-50.
24. Gong C, Hoff JT, Keep RF. Acute inflammatory reaction following experimental intracerebral hemorrhage in rat. Brain Res 2000;871:57-65.
25. Siddique MS, Fernandes HM, Wooldridge TD, et al. Reversible ischemia around intracerebral hemorrhage: a single-photon emission computerized tomography study. J Neurosurg 2002;96:736-41.
26. Masada T, Hua Y, Xi G, et al. Attenuation of intracerebral hemorrhage and thrombin-induced brain edema by overexpression of interleukin-1 receptor antagonist. J Neurosurg 2001;95:680-6.
27. Toulmond S, Rothwell NJ. Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Res 1995;671:261-6.
28. Woo D, Broderick JP, Kothari RU, et al. Does the National Institutes of Health Stroke Scale favour left hemisphere strokes? NINDS t-PA Stroke Study Group. Stroke 1999;30:2355-9.
29. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke 2003;34:2518-32.
30. Price CJS, Warburton EA, Menon DK. Human cellular inflammation in the pathology of acute cerebral ischaemia. J Neurol Neurosurg Psychiatry 2003;74:1476-84.
31. Pozzilli C, Lenzi GL, Argentino C, et al. Peripheral white blood cell count in cerebral ischemic infarction. Acta Neural Scand 1995;71:396-400.
32. Smith CJ, Emsley HCA, Gavin CM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004;4:2.
33. Grundy RI, Rothwell NJ, Allan SM. Dissociation between the effects of interleukin-1 on excitotoxic brain damage and body temperature in the rat. Brain Res 1999;830:32-7.
34. Langhorne P, Stott DJ, Robertson L, et al. Medical complications after stroke: a multicenter study. Stroke 2000;31:1223-9.